Contact Us

PW Case Review Form
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

   * Please describe your case:

What injury have you suffered?

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Orion Stock Falls on News of Potential Stalevo Cancer Link

Apr 5, 2010 | Parker Waichman LLP

Last week's announcement that the U.S. Food & Drug Administration (FDA) was investigating Stalevo for a possible link to prostate cancer has proven to be a drag on the stock price of Finnish drug maker Orion.  According to a Reuters report, last Thursday Orion share were the third most-traded in Helsinki in pre-holiday trade, falling a whopping 10.9 percent.

Orion makes around a third of its total revenues from its key Parkinson's drugs Stalevo and Comtan, distributed by Swiss-based Novartis (NOVN.VX), with half of the sales coming from the U.S. Last year Novartis reported global sales of $554 million for Stalevo and Comtan, Reuters said.

The FDA announced the Stalevo review last Wednesday night. According to the agency, data from a long-term clinical trial, known as STRIDE-PD, unexpectedly found that a greater number of patients taking Stalevo had prostate cancer compared to those taking carbidopa and levodopa (sold as Sinemet), a combination medication used to treat Parkinson’s disease.

Nine out of 245 males had prostate cancer in the study's Stalevo group compared to two out of 222 males in the carbidopa/levodopa group. The incidence rate of prostate cancer was 14 cases/1,000 patient years for Stalevo and 3.2 cases/1,000 patient years for carbidopa/levodopa.

According to Reuters, both Orion and Novartis aid they were working with the FDA as it evaluates the data from STRIDE-PD.


Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo